Early Stage Parkinson's Disease

A precision therapeutics company announced that the first participant has been dosed in a phase 2 clinical trial of a non-dopamine selective modulator to treat those with early-stage Parkinson’s disease.

Individuals with Parkinson’s disease present with reduced thickness of two key components of the retina, which may indicate retinal optical coherence tomography as a vital tool in early disease detection, data show.

The American Academy of Neurology has issued a guideline providing recommendations for treating motor symptoms in people with early Parkinson’s disease.

The dihydropyridine calcium-channel blocker isradipine did not slow the clinical progression of Parkinson’s disease, according to the results of a double-blind, placebo-controlled trial published in Annals of Internal Medicine.